Farrow Jeffrey S 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 17, 2026

AI-generated summary of this filing

Updated Jun 17, 2026

Tarsus (TARS) CFO Jeffrey Farrow Sells Shares to Cover Taxes

What Happened

Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals (TARS), had 27,881 restricted stock units (RSUs) vest and convert into shares on June 15, 2026. Following the settlement, 14,396 of those shares were sold in an open-market "sell-to-cover" transaction on June 16, 2026 at $60.95 per share, generating $877,436. The filings show related derivative/settlement disposition entries tied to the RSU conversion.

Key Details

RSU settlement date: 2026-06-15 (27,881 RSUs settled into shares). (F1, F3, F4)
Open-market sale: 2026-06-16 — 14,396 shares sold at $60.95 for $877,436. (F2)
Filing date: 2026-06-17 (filed timely — within 2 business days of the transaction).
The Form 4 includes a related disposition entry for 27,881 shares at $0 tied to the RSU conversion mechanics (see footnotes).
Shares owned after the transactions: not specified in the provided filing excerpt.
Footnotes: RSUs granted April 24, 2023 under the 2020 Stock Plan; vesting schedule = 25% each June 15 in 2024–2027. The sale was mandated by the issuer's sell-to-cover tax withholding election and was not a discretionary open-market sale by the reporting person. (F1–F4)

Context

These transactions reflect a compensation vesting and routine sell-to-cover for tax withholding, not necessarily a signal of the insider’s view on the stock. RSU settlement converted deferred compensation into shares; a portion was sold to satisfy tax obligations per company policy. There is no indication in the filing of a 10b5‑1 plan or a late filing.

Form 4

Period: 2026-06-15

See Remarks

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-15+27,881→ 71,197 total
Sale
Common Stock
[F2]
2026-06-16$60.95/sh−14,396$877,436→ 56,801 total
Exercise/Conversion
Restricted Stock Units
[F3][F4]
2026-06-15−27,881→ 27,882 total
→ Common Stock (27,881 underlying)

Footnotes (4)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
[F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
[F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
[F4]RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

Signature

/s/ Jeffrey Farrow|2026-06-17

1 file